-
New
Net Present Value Model: Terns Pharmaceuticals Inc’s TERN-501
Empower your strategies with our Net Present Value Model: Terns Pharmaceuticals Inc's TERN-501 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TERN-601 in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TERN-601 in Obesity report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TERN-601 in Obesity Drug Details: TERN-601 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TERN-701 in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TERN-701 in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TERN-701 in Chronic Myelocytic Leukemia (CML,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TERN-501 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TERN-501 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TERN-501 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: TERN-501 is...
-
Net Present Value Model: Terns Pharmaceuticals Inc’s TERN-501
Empower your strategies with our Net Present Value Model: Terns Pharmaceuticals Inc's TERN-501 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Opthea Ltd’s Sozinibercept
Empower your strategies with our Net Present Value Model: Opthea Ltd's Sozinibercept report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
NewGenfit SA Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our Genfit SA Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. Genfit SA (Genfit) is a late-stage biopharmaceutical company. It develops therapeutic and diagnostic solutions for metabolic and inflammatory diseases in liver and gastroenterology diseases. The company’s pipeline products include VS-01-ACLF, nitazoxanide (NTZ), inhibitor SRT-015, CLM-022, VS-02-HE, GNS561, VS-01-HAC, TS-01 and NIS2+. Genfit's products are used in various therapeutic areas including acute-on-chronic liver failure (ACLF), hepatic encephalopathy (HE), cholangiocarcinoma (CCA), urea...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Insulin Human in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Insulin Human in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Insulin Human in Type 1 Diabetes (Juvenile Diabetes)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TERN-101 in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TERN-101 in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TERN-101 in Non-Alcoholic Steatohepatitis (NASH)Drug Details:TERN-101 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TERN-501 in Non-Alcoholic Steatohepatitis (NASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TERN-501 in Non-Alcoholic Steatohepatitis (NASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TERN-501 in Non-Alcoholic Steatohepatitis (NASH)Drug Details:TERN-501 is under development for the treatment...